• Chosa Oncology TO2 warrant exercise runs July 1-14, 2026; unexercised warrants expire worthless on July 14.
• Each TO2 warrant entitles the holder to subscribe for one new share at SEK 0.78.
• Full exercise of 7,951,740 TO2 warrants would issue 7,951,740 shares, raising about SEK 6.2 million before costs.
• CEO Peter Buhl Jensen and COO Ulla Hald Buhl subscribed for 377,073 shares; CCO Claus Frisenberg Pedersen subscribed for 173,454 shares.
• Proceeds earmarked for CLIA certification in 2026, Mount Sinai validation work, US commercialization and partnering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 20260713:BIT:8443:0) on July 13, 2026, and is solely responsible for the information contained therein.